Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
Year: 2014
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12263
Authors: S. Grandy, M. Hashemi, A.‐M. Langkilde, S. Parikh, C. D. Sjöström
Institutions: AstraZeneca (United States), AstraZeneca (Sweden)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Bristol-Myers Squibb, AstraZeneca
OpenAlex ID: W1925323738
